CStone Pharmaceuticals’ exclusive collaboration and license agreement with Blueprint Medicines

Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Fortune Lianjiang Shipping S.A. $1.2 billion financing and delivery of “Hilli Episeyo” vessel

Norton Rose Fulbright has advised Fortune Lianjiang Shipping S.A., an indirect subsidiary of shipping conglomerate CSSC (Hong Kong) Shipping Company Limited, on the US$1.2 billion financing...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Australian Pharmaceutical Industries’s $127.4 million Acquisition of Clearskincare brand’s clinic and products businesses

Allens has advised the founders of Clearskincare on the sale Under the deal, API will take an initial 50.1 per cent stake in Clearskincare’s clinic business...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here